Gene Editing T-Cells to Fight CD7 Blood Cancers
This patent describes a method to treat specific blood cancers by using genetically modified T-cells that are engineered to attack cancer cells without harming themselves or triggering severe immune reactions in the patient.
Patent Number
US 12564648
Status
Active
Filing Date
April 24, 2025
Grant Date
March 3, 2026
Expiration
April 24, 2045
Claims
31
Assignee
Washington University in St. Louis
Inventors
Matthew Cooper, John F. DiPersio
Citations
0 forward · 73 backward
What it covers
This patent outlines a method for treating CD7 positive hematologic cancers, which are types of blood cancer, in humans. It involves administering specially modified human T cells. These T cells are engineered to express a Chimeric Antigen Receptor (CAR) that specifically binds to a protein called CD7, which is found on the cancer cells (Claim 1a). Crucially, these T cells have two genetic modifications: a first 'indel' (a small insertion or deletion) in their own CD7 gene, making them 'CD7 deficient' (Claim 1b), and a second indel in their T cell Receptor Alpha Chain (TRAC) gene, making them 'TRAC deficient' (Claim 1c). The CD7 modification prevents the CAR-T cells from attacking each other (a problem called fratricide, Claim 7), while the TRAC modification helps prevent the modified cells from attacking the patient's healthy tissues (called alloreactivity or Graft-versus-Host Disease, Claim 10). For example, this method could be used to treat T-cell acute lymphoblastic leukemia (T-ALL) by infusing these specially prepared T cells into a patient (Claim 11, 12).
What it doesn't cover
- —Does not cover CAR-T cells that target antigens other than CD7 (e.g., CD19 or BCMA).
- —Does not cover CAR-T cells that lack a specific genetic modification (indel) in their own CD7 gene.
- —Does not cover CAR-T cells that lack a specific genetic modification (indel) in their T cell Receptor Alpha Chain (TRAC) gene.
- —Does not cover CAR-T cells where the genetic modifications are not 'indels' (e.g., gene insertions or point mutations).
- —Does not cover methods for treating cancers that are not CD7 positive hematologic cancers.
- —Does not cover CAR-T cells modified to prevent fratricide or alloreactivity through non-genetic means or different genetic targets.
The clever bit
The truly clever part is the dual genetic modification of the CAR-T cells themselves. By making the T-cells deficient in CD7, they become 'fratricide-resistant,' meaning they won't attack each other even while targeting CD7 on cancer cells. Simultaneously, disabling the T cell Receptor Alpha Chain (TRAC) prevents the engineered cells from causing harmful immune reactions against the patient's healthy body, a significant safety improvement.
Why it matters
Chimeric Antigen Receptor (CAR-T) cell therapy is a powerful new way to fight cancer, but it faces challenges, especially when targeting T-cell cancers because the cancer cells and the therapeutic T-cells often share surface markers like CD7. This patent addresses two major problems in CAR-T therapy: 'fratricide,' where the engineered T-cells attack each other, and 'alloreactivity,' where the T-cells attack healthy patient tissues. By genetically modifying the T-cells to be resistant to these issues, this invention aims to make CAR-T therapy safer and more effective for a wider range of blood cancers, specifically those that express CD7.
Real-world examples
- 1.CAR-T cell therapies for blood cancers
- 2.Gene-edited cell therapies
- 3.Treatments for T-cell acute lymphoblastic leukemia (T-ALL)
- 4.Treatments for T-cell lymphoblastic lymphoma (T-LBL)
- 5.Treatments for T-cell non-Hodgkin's Lymphoma (T-NHL)
Generated by PatentBrief · Not legal advice · patentbrief.org
US 12564648 · 2026